BEGIN:VCALENDAR
VERSION:2.0
METHOD:PUBLISH
PRODID:-//Telerik Inc.//Sitefinity CMS 14.4//EN
BEGIN:VTIMEZONE
TZID:Mountain Standard Time
BEGIN:STANDARD
DTSTART:20231102T020000
RRULE:FREQ=YEARLY;BYDAY=1SU;BYHOUR=2;BYMINUTE=0;BYMONTH=11
TZNAME:Mountain Standard Time
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20230301T020000
RRULE:FREQ=YEARLY;BYDAY=2SU;BYHOUR=2;BYMINUTE=0;BYMONTH=3
TZNAME:Mountain Daylight Time
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
DESCRIPTION:Toxicology is a borrowing science\, using what is known about t
he physicochemical properties of a test article (e.g.\, potential therapeu
tic) and biology of the intended target (e.g.\, receptor) hypothesized to
modulate the disease of interest. Prior to entering first in human clinica
l trials\, rigorous in silico\, in vitro and in vivo testing must produce
tolerability data supporting safe use of the test article for its intended
use (i.e.\, drug label). Topics covering early and required toxicology te
sting will be covered.\n\nPresented by: Kenneth J. Olivier Jr.\, PhD\, Hea
d of Toxicology and various drug development activities at Orange Grove Bi
o\, VP of Development at TScan Therapeutics\, Inc.\, Director of nonclinic
al development at Boston Immune Technologies and Therapeutics\, President
Olivier KOnsulting\n
DTEND:20220407T000000Z
DTSTAMP:20240329T052806Z
DTSTART:20220406T220000Z
LOCATION:
SEQUENCE:0
SUMMARY:Is it Safe? Toxicology in Therapeutic Development with Kenneth J. O
livier Jr.\, PhD
UID:RFCALITEM638472652869630335
X-ALT-DESC;FMTTYPE=text/html:Toxicology is a borrowing science\, using what
is known about the physicochemical properties of a test article (e.g.\, p
otential therapeutic) and biology of the intended target (e.g.\, receptor)
hypothesized to modulate the disease of interest. Prior to entering first
in human clinical trials\, rigorous in silico\, in vitro and in vivo test
ing must produce tolerability data supporting safe use of the test article
for its intended use (i.e.\, drug label). Topics covering early and requi
red toxicology testing will be covered.
\n
\n
Presented by : Kenneth J. Olivier Jr.\, PhD\, Head of Toxicology and various drug devel opment activities at Orange Grove Bio\, VP of Development at TScan Therape utics\, Inc.\, Director of nonclinical development at Boston Immune Techno logies and Therapeutics\, President Olivier KOnsulting
\n END:VEVENT END:VCALENDAR